SELLAS’ financial loss underscores the high stakes of its leukemia trials, potentially impacting future funding and strategic directions.
The post SELLAS Life Sciences posts $10.1M Q3 loss as pivotal leukemia trial results approach appeared first on Crypto Briefing.